Oncogenic human papillomaviruses (HPVs) are in most cases eliminated by intervention of T cells. As many other pathogens, these oncogenic HPVs belong to an ancient and diverse virus family. Therefore, we found it relevant to investigate the potential and limitations of inducing a broad response-either by inducing cross-reactive T cells or by administering a polyvalent vaccine. To test these strategies, we designed three ancestral and two circulating sequences based on the two domains of the E1 and E2 proteins of papillomaviruses (PVs) that exhibit the highest degree of conservation in comparison with the other PV proteins. The PV sequences were fused to a T cell adjuvant, the murine invariant chain and encoded in a recombinant adenoviral vector which was administered to na€ ıve outbred mice. By measuring T cell responses induced by these different vaccines and towards peptide pools representing three circulating strains and a putative ancestor of oncogenic HPVs, we showed that the ancestral vaccine antigen has to be approximately 90% identical to the circulating PVs before a marked drop of~90% mean CD8+ T cell responses ensues. Interestingly, the combination of two or three type-specific PV vaccines did not induce a significant decrease in the CD8+ T cell response to the individual-targeted PV types. Polyvalent HPV vaccine based on the E1 and E2 proteins seem to be capable of triggering responses towards more than one type of PV while the cross-reactivity of ancestral vaccine seems insufficient in consideration of the sequence diversity between HPV types.
Introduction
In most cases, pathogens belong to a very diverse and large family as it is the case for HIV, HCV, HPV and Plasmodium falciparum. Therefore, developing vaccine strategies that can trigger more than one strain of pathogen has been a major focus in the vaccinology field. For that purpose, researches have been mostly focuses on either developing cross-reactive vaccines using consensus/ancestral sequences or developing polyvalent vaccines. Induction of cross-reactivity is appealing as one vaccine can target many types of viruses within the family, but the difficulty to induce such a response increases with the degree of diversity. A polyvalent vaccine might then be more feasible, but variability of responses to the individual types in the mixture may ultimately limit the number of targeted types that can be included in such vaccines.
Oncogenic human papillomaviruses (HPVs) are among the viruses that belong to a highly diverse family [1] . Until now, three prophylactic HPV vaccines (Gardasil, Gardasil-9 and Cervarix) have been licensed. They are polyvalent vaccines and Gardasil-9 that has been recently introduced can induce responses towards nine different HPV types [2] . Despite their nearly complete efficacy against vaccinetargeted papillomavirus (PV) types in na€ ıve women [3] , developing therapeutic vaccines is yet an important focus in the scientific literature because of the low uptake of the preventive vaccines [4] and their poor therapeutic efficacy [3] . Therefore, exploring the possibility to develop either a cross-reactive T cell-based vaccine or a polyvalent vaccine has additional relevance for combating HPV infections.
For attempts to induce cross-reactive responses and stimulate normal HPV elimination mechanisms, we focused on the E1 and E2 proteins, which are the most conserved among the HPV early proteins. Importantly, the selection of the E1 and E2 proteins also has consequences for the clinical targeting potential of a vaccine. The E1 and E2 early proteins of HPVs are involved in the replication of the virus genome and the regulation of E6 and E7 oncogenic proteins [5] . As these two proteins are highly expressed during chronic infection and low-grade cervical intraepithelial neoplasia (CIN) [6, 7] , we are limiting ourselves to targeting the early stage of the infection before the cancer is established. This is in contrast to the majority of therapeutic strategies that targets the E6 and E7 oncogenes and therefore target the more advanced lesions and cancers [5, 8] . Notably, it is at the early stages when most spontaneous regression occurs [9] and we therefore anticipate that enhancing this regression rate is more feasible than achieving efficacy against malignancy. Regression is correlated with T cell infiltrations in warts [10] and with E2-specific T cell responses in previously exposed, now uninfected children [11] , and therefore, vaccination at this time could potentially boost the natural immunity to HPV for infected women.
We used Bayesian methods to reconstruct phylogenic trees and ancestral sequences having different degrees of similarity to the circulating sequences. The ancestral sequences selected for functional studies included one corresponding to the root of a phylogenetic tree of all oncogenic human and macaques PVs (CDSE1E2 antigen) as well as two other sequences that were ancestral to the clades containing HPV16/31/35 and HPV18/45, respectively. We also designed two vaccines encoding circulating human and macaques PVs sequences (HPV16E1E2, MfPV3E1E2). The E1 and E2 sequences of Macaca fascicularis type 3 (MfPV3) were also included as it had been shown to be closely related to HPV16 and associated with both persistence and intraepithelial neoplasia [12, 13] ; thus, MfPV3 would potentially offer a test model for vaccines against persisting PV infection.
In this study, each of our designed antigens (ancestral and circulating) was fused to a T cell adjuvant, the murine invariant chain (mIi), encoded in the replication deficient human adenovirus type 5 (Ad5) and tested in na€ ıve outbred mice. Fusion of the MHC class II-associated invariant chain (Ii) to a vaccine antigen leads to an increase in the antigen presentation on the surface of transduced dendritic cells (DCs) which has been correlated with an increase in the CD4+ and CD8+ T cell proliferation and a significant rise in the magnitude of the CD8+ T cell responses independent of the CD4 help [14] . Since the design of this novel technology in [2005] [2006] [2007] [2008] , it has been used with different antigens and tested in different strains of mice and primates [14] [15] [16] and has been highlighted by others to be among the best-described T cell adjuvants for adenovirus vectored vaccines [17] . We have never observed reduced responses to Ii-linked antigen as compared to unlinked antigen [14, 15, 17, 18] , and in a recent study, Capone et al. [15] showed that chimpanzee adenovirus vector encoding the non-structural (NS) protein of the genotype 1b of HCV was able to induce a relatively similar T cell response to the NS protein of the HCV genotype 3a.
Importantly, the breadth of the detectable vaccine-induced response was enhanced by fusing the NS protein to the mIi. Therefore, the mIi is a relevant tool to include in our vaccine constructs and may increase the detection of lowmagnitude responses that would go unnoticed without the use of the invariant chain sequence.
By using the CDSE1E2, HPV18_45E1E2, HPV16_ 31_35E1E2, MfPV3E1E2, HPV16E1E2 sequences and peptide pools targeting E1 and E2 from CDS, HPV16, HPV18, MfPV3 we showed that ancestral sequences based on the E1 and E2 proteins of papillomaviruses had to share close to 90% homology to the circulating PVs to induce a consistent T cell response at a level similar to the vaccine antigen. Vaccines with less similarity to the applied peptide pools rapidly dropped in response magnitude and consistency in outbred mice. We also showed that the T cell responses specific to each vaccine antigen that was induced after vaccination with up to three vaccines at once were similar to the T cell responses after immunization with one vaccine. A vaccine cocktail or a polygenic vaccine encoding up to three antigens could therefore theoretically achieve targeting of a large fraction of the circulating oncogenic strains.
Materials and methods
Mice. Female CD1 mice were obtained from Scanbur (Denmark) and were acclimated for at least one week prior to vaccination. For all experiments mice were between seven and nine weeks of age at the start. The experimental procedure was approved by the national ethics committee on experimental animal welfare (dyreforsøgstilsynet) and performed according to the Danish guidelines.
Generation of the different PVs ancestral sequences. First, multiple alignments for the E1 and E2 protein of the most frequent HPVs were performed using the software MAFFT [19] . For each alignment, the best-fitting amino acid substitution models was then determined using the PROTTEST3 software [20] . For both protein data sets, this was found to be JTT + I + G. Phylogeny and ancestral sequences were then inferred using the software MRBAYES version 3.1.2 [21] . For each data set, the program was run for at least 3,000,000 generations, with two parallel runs of five chains each. Convergence of the Markov chain Monte Carlo run was checked using the software TRACER (Tracer version 1.6, available http://beast.bio.ed.ac.uk/ Tracer) and also by using the convergence diagnostics output by MrBayes. Finally, we used software written by the authors to automatically infer and remove subsequences corresponding to inserts that most likely were not present in a given ancestral sequence. Once the ancestral sequences were generated, the relatively conserved N-and C-terminal domains of E1 and E2 were selected and separated by GS linkers. The sequences are listed in Figure S1 .
The CDSE1E2 has also been applied in a primate immunogenicity and efficacy study against Macaca fascicularis papillomaviruses (Ragonnaud et al., manuscript accepted, December 2016) Adenoviral vector production and immunizations. The above ancestral antigens (CDSE1E2, HPV16_31_35E1E2, HPV18_45E1E2) and the PV circulating antigens (HPV16E1E2 and MfPV3E1E2) were subcloned directly after the full length of the mIi within the same ORF. The mIi was in a transgene expression cassette of a shuttle plasmid and flanked by a CMV promoter (cytomegalus promoter) with tetracycline operator (TetO) sites [22] and a SV40 polyA (simian virus 40 poly A signal). The cassette was then inserted into the E1 region of an E1/E3-deleted recombinant human adenovirus type 5 (Ad5) genomic plasmid by homologous recombination in BJ5183. The newly generated plasmid containing the Ad5 virus genome with the relevant sequence in the E1 locus was linearized and transfected in T-Rex-293 cell line (Thermo Scientific, Waltham, Massachusetts, USA). Each virus was propagated in this cell line and purified by CsCl gradient ultracentrifugation as previously described [23] . The genome of the purified viruses was isolated and genomic DNA sequenced to verify the newly inserted sequence into the E1 deleted locus and digest by restriction enzymes digestion for further quality control. The number of virus particles (VPs) was identified by measuring the OD value of the purified virus on a NanoDrop-2000 (Thermo Scientific). The infectious virus titre (IFU) for each vaccine was determined at the same time with the Adeno-X Rapid Titer system (Clontech, Mountain View, CA, USA).
All mice were immunized subcutaneously (s.c.), behind the foot pad in the right leg with 2 9 10 7 IFU of the corresponding vaccines in 30 ll of PBS as in a number of previous studies using Ii adjuvant vaccines [14, 18, [24] [25] [26] [27] .
Peptides. Peptide pools used in this study contained 96 peptides for the CDSE1 protein, 42 peptides for the CDSE2 protein, 94 peptides for the HPV16E1 protein, 41 peptides for the HPV16E2 protein, 97 peptides for the HPV18E1 protein, 40 peptides for the HPV18E2 protein, 96 peptides for the MfPVE1 protein, 39 peptides for the MfPV3E2 protein. To span the entire sequence of each protein, peptides were 16 a.a. long and overlap by 11 a.a. These different peptides were purified and pooled by JPT (Germany) and shipped to Denmark in a lyophilized form.
Flow cytometry. Spleens were collected from mice 14 days after immunizations, and each of them was mashed through a net to obtain a single cell suspension that was then stimulated at 37°C and 5% CO 2 for 5 h with 1 lg/ml of relevant peptide pools and 3 lM of Monensin. After incubation, cells were stained according to the standard protocols [28, 29] . Briefly, cells were first stained using the following surface anti-mouse antibodies (Biolegend, San Diego, California, USA): CD8_PerCP.Cy5.5, CD4_Pe, CD44_FITC, then fixed using a 1% paraformaldehyde (PFA) solution and finally permeabilized to allow the entry of the anti-mouse IFN-c_APC antibody (Biolegend). The data were collected on the LSRII and FORTESSA instruments (BD Biosciences, Denmark).
Determination of the percentage of identity between the vaccine antigens and the proteins used for splenocyte stimulation. The percentage of identity between the vaccines sequences and the proteins sequences (used to produce the different peptide pools for the flow cytometry assay) was calculated by multi-alignment using the algorithm 'blastp' on the NCBI website.
Statistical analysis. Graphs and statistical analysis were performed using PRISM software (version 5, La Jolla, California, USA). Quantitative results were compared using two-tailed Mann-Whitney (non-parametric) test. P Values (P) >0.05 were non-significant (ns) values, P ≤ 0.05 were denoted '*', P ≤ 0.01 were denoted '**' and P ≤ 0.001 were denoted '***'.
Results

Amino acid sequence homologies between the vaccine antigens and PVs proteins
After phylogenetic reconstruction based on the E1 and E2 proteins of oncogenic HPVs, we selected three ancestral sequences (CDSE1E2, HPV16_31_35E1E2 and HPV18_45E1E2) that correspond to different internal nodes in the phylogenetic tree, as well as two existing PV sequences (MfPV3E1E2 and HPV16E1E2). These different sequences (listed in Figure S1 ) were fused to the T cell adjuvant, the mIi [14] and encoded in a replication deficient Ad5 as illustrated in Fig 1A. Using standard multiple-alignment tools, we identified the percentage of amino acid homologies between the vaccine antigen sequences and the peptide pools covering the E1 and E2 proteins from ancestral and circulating PVs (Fig. 1B) . Through these different combinations, we cover a distance from 50 to 100% identity providing us with a novel platform to study cross-reactivity based on the E1 and E2 proteins.
A high percentage of identity between ancestral and circulating PVs amino acid sequences is necessary to induce robust cross-reactive CD8+ T cell responses
We next investigated the ability of our different vaccine constructs to induce cross-reactive T cell responses. For that purpose, outbred mice were vaccinated with one of the five vaccines and 14 days later, we analysed the CD8+ T cell responses towards peptide pools covering the E1 and E2 proteins of CDS, HVP18, HPV16 and MfPV3. Here, each vaccinated group was able to induce a strong CD8+ T cell response towards the E1 vaccine-encoded antigen in an average of 6 9 10 5 IFN-c producing CD8+ T cells ( Fig. 2A) . Only the vaccine encoding the ancestral sequence corresponding to the internal node closest to HPV18 and HPV45 (Ad5_mIi_HPV18_45E1E2) and sharing about 92% of identity to the E1 protein of HPV18 was able to raise a similar HPV 18-specific CD8+ T cell response in all vaccinated mice as it was against homologous vaccine antigens ( Fig. 2A,B) . When the percentage of homology was lower than 92%, some, but not all, vaccinated mice were able to raise cross-reactive CD8+ T cell responses and for those responding mice the responses were significantly lower than against vaccine antigens with an average drop of about 10-fold ( Fig. 2A,  B) . The CD8+ T cell responses raised against the E2 protein were not as consistent as against the E1 protein.
Certainly, not all vaccinated mice were able to induce CD8+ T cell responses against the E2 protein encoded in the vaccines, and this antigen was also found to provide poor or non-existent cross-reactivity (Fig. 2C,D) . Occasionally potent responders were detected including quite prominently for the 76% homology group (Fig. 2D) . To obtain an idea of the overall responses, we added the percentage of the IFN-c producing CD8+ T cells after E2 stimulation to the percentage after E1 stimulation. This did not result in a higher number of responders which can be explained as the few E2 responders had also responded to the E1 protein (Fig. 2E,F) .
Combination of up to three PV vaccines does not negatively affect the induced CD8+ T cell responses
The magnitude of the PV-specific T cell responses induced after vaccination to eliminate PV infections is still unknown. Therefore, we found it interesting to investigate whether the combination of two or three vaccines could maintain the magnitude and/or consistency of the T cell responses specific to the vaccine-encoded antigens. For that purpose, we immunized three groups of outbred mice, one group with the Ad5_mIi_MfPV3E1E2 vaccine, a second group with the Ad5_mIi_MfPV3E1E2 and Ad5_mIi_HP-V16E1E2 vaccines and a last group with the Ad5_mIi_MfPV3E1E2, Ad5_mIi_HPV16E1E2 and Ad5_mIi_CDSE1E2 vaccines. As in the previous 7 infectious unit (IFU). All mice were euthanized 14 days later and total number of splenic CD8+ T cells responding to with IFN-c production to peptide pools of the ancestral (CDS) and circulating (HPV16, HPV18, MfPV3) E1 and E2 proteins of PVs (A, C and E). These T cell responses were grouped depeding on the distances (% of a.a. homology) between the vaccines' antigen and the peptide pools of the E1 and E2 proteins (B, D and E). These distances were characterized in the previous figure 1. The E1/E2 T cell responses (E and F) correspond to the addition of the % of IFN-c CD8+ T cells responding to the E1 pools and to the % of IFN-c CD8+ T responding to the E2 pools. Splenocytes were gated on CD8+, CD44+, and IFN-c+ T cells. Each dot and bar represents a mouse and the mean, respectively. This experiment was performed twice and the data were pooled. 'ns' denotes for non-significant. of up to three vaccines did not have any effect on the MfPV3E2-specific CD8+ T cell responses. The last group of mice that received three vaccines including the Ad5_mIi_CDSE1E2 vaccine was also able to induce a potent CD8+ T cell response to the E1 protein of CDSE1E2 antigen (Fig. 3A) that was similar to the group of mice that received only this vaccine in the previous experiment ( Fig. 2A) . A slight, but not statistically significant, decrease in the E1 HPV16-specific CD8+ T cell response was observed in the group of mice that received three vaccines in comparison with the combination of the two vaccines (Fig 3A) , but all animals responded against all antigens used for immunization. As seen in the previous experiment, the E2-specific CD8+ T cell responses induced by any of the vaccines were low in every group (Fig. 3B) .
Similar conclusions concerning the CD4+ T cell responses
Adenoviral vaccines, even without using the Ii adjuvant, are first and foremost potent stimulators of CD8+ T cell responses [30, 31] . Nevertheless, the CD4+ T cells have been shown to have an important role in the regression of HPV infections [10, 23, 32, 33] . Therefore, we also analysed the CD4+ T cell response after vaccination at the same time as the CD8+ T cell response was measured. The vaccine-induced CD4+ T cell responses were found to be much lower than the CD8+ T cell responses, and we therefore decided to focus on the total E1-and E2-specific CD4+ T cell responses. In this analysis the results for each experiment were similar to the CD8+ T cell responses and again, a minimum of 90% of homology between the PV ancestral sequences and the circulating PVs was necessary to induce a CD4+ T cell response similar in magnitude to the vaccine antigen-specific CD4+ T cell response (Fig. 4A,B) . Also, the combination of up to three vaccines was still as potent as a single vaccine against the same specificity (Fig. 4C) .
Discussion
The aim of the study was to investigate the possibly to design a therapeutic adenoviral vaccine that can elicit T cell responses specific to more than one type of circulating oncogenic papillomavirus. For that purpose, two approaches were tested. The first one was to analyse the induced cross-reactive T cell responses after vaccination with adenoviral vectors encoding E1 and E2 ancestral sequences located at different distances to circulating PVs and to identify the similarity requirement for induction of consistent responses. The second approach was to investigate the possibility of combining several vaccines and observe whether we still preserve the T cell responses to each targeted PV.
When we investigated the ability of these different ancestral vaccines at inducing cross-reactive T cell responses, we discovered that at least 90% of amino acid identity between the vaccine antigen and the circulating PV strains was necessary to match vaccine antigen-specific T cell responses. A percentage of homology lower than 90% induced a significant reduction in the cross-reactive T cell responses towards targeted PVs and more variation within the responding mice with a high frequency of nonresponders. For the prospects of using ancestral sequences to generate very broadly effective vaccines against PVs, this lack of consistency was a sobering finding, but it may be sufficient for cross-reactive vaccines against less diverse pathogens such as HIV-1 with 90 to 85% of homology between clades in the major structural proteins pol and gag, respectively [34] . The rather strict homology requirement we observed as necessary to maintain robust T cell responses is superficially different from the Capone et al. [15] study where only 70% identity (as determined by multiple alignment of the amino acid sequences) between the two non-structural (NS) proteins was shared and where crossreactivity was found in all of the vaccinated outbred mice. As we used the human Ad5 vector that has shown similar potency to the chimpanzee adenoviral vectors [30] and the mIi which was also used in the Capone et al. [15] study, our platform should have been performing similarly. A potential factor to explain the discrepancies is the size of our E1/ E2 antigen that is much smaller than the NS protein used in Capone et al. [15] . A shorter antigen will arguably tend to have fewer MHC binding peptides and therefore less epitopes of which a fraction has the capacity to inducing cross-reactive epitopes. Looking at the individual responding animals in Capone et al. [15] , it is also evident that the animals responded with heterogeneity and the animals had responses towards four to six of six included homologous peptide pools. Our antigen (length~700 a.a.) is considerably shorter than the NS antigen (length~2000 a.a.), and in this light it may not be surprising that we saw less homogeneity in the responses and only occasionally responses towards the E2 protein (~200 a.a.) in comparison with the E1 protein (~500 a.a.). Also, if our vaccines induce responses to fewer epitopes, it is less of a surprise that it sometimes fails completely against strains with more than 10% of dissimilarity. Notably, the mean of the responses we observed were approximately 10-fold to 15-fold lower which is not too different from the responses in Capone et al. [15] . Additionally, it is possible that we, by selecting the most conserved regions of the E1 and E2 proteins, may also have selected protein domains that are less immunogenic than the highly diverse regions. Such adaptation has been recently reported to have happened during the course of HIV evolution [35] . Such adaptation might also help explain why the E2 protein was poorly immunogenic in most measurements in the study. As a curiosity in our data set, we did observe the group of 76% of E2 homology responding more potently than the group of 83-86% of homology, but the group of 76% of is also the smallest data set and it might be a chance event.
Importantly, while the ability to eliminate PV infections has been shown to be genetically linked to genes within the immune system [23] and correlated with T cell infiltration [10] , the PV-specific T cell responses appear difficult to detect in the blood [36] . Therefore, a low crossreactive T cell responses induced after vaccination with an adenovirus vector encoded the PV ancestral sequence might be sufficient to eliminate oncogenic PV infections, if it could only be consistently induced.
In this study, as an alternative to the ancestral antigen design we also showed that it was possible to combine up to three PV vaccines while preserving the T cell responses to each of the included PV antigens. A vaccine cocktail or a polygenic vaccine encoding up to three antigens could theoretically achieve targeting of a large fraction of the circulating oncogenic strains. These data are different from the results reported in the Larke et al. [37] study (2007) which showed that combining single-clade HIV-1 vaccines reduced the breadth of induced T cell responses, although simultaneous injection into anatomically separated sites could increase these T cell responses. We did not apply different injection sites to avoid immunodominance Fig. 2 and (C) refer to the experiment illustrated in Fig. 3 . As it was mentioned in Fig. 2 legends, the E1/E2 T cell responses correspond to the addition of the % of IFN-c CD8+ T cells responding to the E1 pools and the % of IFN-c CD8+ T responding to the E2 pools. 'ns' denotes for non-significant. between the antigens, as this defies the purpose of combining the vaccines to make a useful polyvalent vaccine formulation, but we nevertheless achieved strong responses to each included antigen. This could be a benefit of the Ii adjuvant that has demonstrated improved capacity to compete with vector derived immune responses for induction of broader responses [38] .
From our findings, it is clear that a single short ancestral sequence cannot induce the coveted consistent E1-and E2-specific responses, and that relatively close sequence similarity is needed, but we have obtained clues to how this could be achieved. Simply mixing vaccine vectors seems to be a viable strategy and would presumably induce broad if not exactly global coverage. When analysing the differences and similarities to the study by Capone et al. [15] , inclusion of larger fragments of the papillomavirus genomes and potentially encoding multiple antigens could be seen as logical steps forward.
Accordingly, the information provided in this study may bring us closer to obtain a therapeutic vaccine that can trigger more than one type of papillomavirus. Furthermore, the basic conclusions obtained may find relevance for vaccination attempts against other variable T cell antigens.
